Close Menu

NEW YORK (GenomeWeb) — Bristol-Myers Squibb and H3 Biomedicine said today that they have partnered to investigate the therapeutic potential of H3's RNA splicing technology.

H3 — a Cambridge, Massachusetts-based subsidiary of Japanese drugmaker Eisai — is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Oct
03
Sponsored by
Agilent

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10
Sponsored by
Roche

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
21
Sponsored by
Agilent

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.